-+ 0.00%
-+ 0.00%
-+ 0.00%

IGC Pharma Completes Six-Week Treatment Phase Of CALMA For All Its 170 Participants; Topline Results Anticipated During December 2026/January 2027 Timeframe

Benzinga·11/18/2026 13:09:36
Listen to the news

Final participant completes dosing in 170-participant trial; topline results anticipated during the December 2026/January 2027 timeframe

POTOMAC, MD / ACCESS Newswire / November 18, 2026 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational therapies for Alzheimer's disease, today announced the completion of the six-week treatment phase of CALMA for all its 170 participants.

The final participant has completed dosing, and all required treatment-period visits and assessments are complete. The trial randomized 170 participants with agitation in Alzheimer's dementia across clinical sites in the United States and Canada, exceeding its original enrollment target of 146 participants.

With the treatment phase complete, CALMA is advancing through final data verification, reconciliation, and quality-control activities ahead of database lock, unblinding, and independent statistical analysis.